Good response with zinc acetate monotherapy in an adolescent affected by severe Wilson disease


https://doi.org/10.4081/pmc.2012.67
Vol. 34 No. 2 (2012)
Submitted: 18 November 2014
Accepted: 18 November 2014
Published: 30 April 2012
Haemolytic anaemia, Wilson disease, zinc acetate
Abstract Views: 1121
PDF: 1069
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • M.G. Marazzi
    mgraziamarazzi@ospedale-gaslini.ge.it
    Department of Paediatrics, University of Genoa, Infectious Diseases Unit, G. Gaslini Children’s Hospital, Genova, Italy.
  • S. Giardino Paediatric Haematology and Oncology Unit, G. Gaslini Children’s Hospital, Genova, Italy.
  • C. Dufour Paediatric Haematology and Oncology Unit, G. Gaslini Children’s Hospital, Genova, Italy.
  • M. Serafino Department of Paediatrics, University of Genoa, Genova, Italy.
  • D. Sperlì Department of Paediatrics, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
  • R. Giacchino Infectious Diseases Unit, G. Gaslini Children’s Hospital, Genova, Italy.
We describe a 17-year-old girl with haemolytic anaemia as presentation of Wilson disease. The diagnosis was based on the findings of < 20 mg/dl ceruloplasmin serum level, Kayser-Fleischer ring and Coombs-negative haemolytic anaemia. Genetic testing revealed the presence of the H1069Q heterozygous mutation. The patient was treated with Zinc acetate monotherapy, with good response, maintened after 22 months. This case emphasizes the importance of recognizing atypical clinical presentation of Wilson disease, which must always be considered in patients with Coombs-negative haemolytic anaemia. The good clinical response to treatment with zinc acetate monotherapy in our case might lend to consider the use of zinc monotherapy as initial therapy also in symptomatic patients with Wilson disease under close clinical observation. Clinical trials are needed to provide evidence for use of zinc monotherapy as first-line therapy in symptomatic patients with Wilson disease.

Marazzi, M., Giardino, S., Dufour, C., Serafino, M., Sperlì, D., & Giacchino, R. (2012). Good response with zinc acetate monotherapy in an adolescent affected by severe Wilson disease. La Pediatria Medica E Chirurgica, 34(2). https://doi.org/10.4081/pmc.2012.67

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC